Varenicline to help adults stop vaping

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, placebo-controlled Phase 2 trial in adults seeking help to stop regular e-cigarette use. Participants are randomly assigned to 12 weeks of varenicline (titrated to 2 mg daily) or matching placebo, plus brief counseling and self-management resources. Research visits occur every three weeks during treatment with a final follow-up at week 26 to measure quit rates and changes in health biomarkers. The study also looks at predictors and moderators of who benefits most from treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* report daily use of an e-cigarette containing nicotine
* live in Connecticut or South Carolina

Exclusion Criteria:

* regular use of other tobacco products besides e-cigarettes
* medical contraindications for varenicline use
* current treatment for tobacco cessation
* lack proficiency in English

Where it's running

• Yale Cancer Center/Smilow Cancer Hospital at Yale-New Haven
  New Haven, Connecticut, United States Recruiting
• Hollings Cancer Center at MUSC (HCC)
  Charleston, South Carolina, United States Recruiting

Study contacts

• Principal investigator: Lisa Fucito, PhD — Yale University
• Study coordinator: Lisa Fucito, PhD
• Email: lisa.fucito@yale.edu
• Phone: 2032001470

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TUBSIS 2.0 — an online program to help adults reduce or quit smoking and vaping

  This program tests whether a free, anonymous, 4-week web-based course using mindfulness, self-compassion, and behavior-change techniques helps German-, English-, and Turkish-speaking adults who smoke or vape reduce or quit tobacco.

  Recruiting University of Zurich · Zurich · NCT07568483

• Social media support groups to help teens and young adults quit vaping

  This pilot tries a social-media group program called the Quit the Hit Toolkit to help adolescents and young adults who vape stop using nicotine.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07540780

• Sex differences in how menthol e-cigarettes appeal to people who smoke

  This study tests whether men and women differ in how menthol e-cigarettes with or without nicotine appeal to smokers who have used e-cigarettes before.

  Recruiting Yale University · New Haven, Connecticut · NCT07398976

• Varenicline plus enhanced TMS to help adults quit smoking and vaping

  This study tests whether adding active enhanced accelerated transcranial magnetic stimulation (aTMS) to varenicline helps adults 18–65 quit nicotine use more effectively than varenicline with sham stimulation.

  Recruiting Phase 4 Massachusetts General Hospital · Boston, Massachusetts · NCT07145866

• QuitVaping behavioral program with texting support to help teens stop vaping

  This trial will try QuitVaping plus extra texting to see if it helps teens aged 14–18 who vape nicotine quit more than standard education and referral alone.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT06765291

• Smoky Futures: Danish Adolescent Nicotine Use over Time

  This observational cohort follows Danish youths ages 15–25 to see how cigarette, e-cigarette, and other nicotine use begin, change, and affect health and education over several years.

  Recruiting University of Southern Denmark · Copenhagen · NCT07910331

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.